Zura Bio Limited
ZURAHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeZura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The $587.4M market capitalization puts ZURA squarely in small-cap range for its industry. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Market Cap
$587.4M
Beta
-0.03
P/E (TTM)
—
P/E (Fwd)
-10.51
EPS (TTM)
$-1.12
EPS (Fwd)
$-0.58
ROE
-51.0%
ROA
-31.2%
Cash
$205.1M
Total Debt
$0
Free CF
-$48.8M
52W Change
183.2%
Annual Financials
Cash vs Debt
Where ZURA stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, ZURA finished 4.05% above its 150-day moving average ($5.43) and 8.45% above its 200-day moving average ($5.21). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ZURA overbought or oversold?
At the September 2, 2026 close, ZURA's RSI(14) was 46.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Zura Bio Limited reports $205.1M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$48.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -51.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Zura Bio Limited typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ZURA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.